- Home
- AS vs PODD Comparison
AS vs PODD Comparison
Compare AS & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AS
- PODD
- Stock Information
- Founded
- AS 1950
- PODD 2000
- Country
- AS Finland
- PODD United States
- Employees
- AS N/A
- PODD N/A
- Industry
- AS
- PODD Medical/Dental Instruments
- Sector
- AS
- PODD Health Care
- Exchange
- AS NYSE
- PODD Nasdaq
- Market Cap
- AS 15.7B
- PODD 17.2B
- IPO Year
- AS 2024
- PODD 2007
- Fundamental
- Price
- AS $22.16
- PODD $246.80
- Analyst Decision
- AS Strong Buy
- PODD Buy
- Analyst Count
- AS 9
- PODD 17
- Target Price
- AS $33.00
- PODD $294.65
- AVG Volume (30 Days)
- AS 4.5M
- PODD 878.5K
- Earning Date
- AS 05-20-2025
- PODD 05-08-2025
- Dividend Yield
- AS N/A
- PODD N/A
- EPS Growth
- AS N/A
- PODD 96.55
- EPS
- AS 0.14
- PODD 5.78
- Revenue
- AS $5,183,300,000.00
- PODD $2,071,600,000.00
- Revenue This Year
- AS $18.01
- PODD $20.53
- Revenue Next Year
- AS $13.08
- PODD $17.42
- P/E Ratio
- AS $158.29
- PODD $42.67
- Revenue Growth
- AS 17.79
- PODD 22.07
- 52 Week Low
- AS $10.11
- PODD $160.19
- 52 Week High
- AS $34.00
- PODD $289.46
- Technical
- Relative Strength Index (RSI)
- AS 37.35
- PODD 42.59
- Support Level
- AS $21.15
- PODD $241.54
- Resistance Level
- AS $23.36
- PODD $258.00
- Average True Range (ATR)
- AS 1.92
- PODD 13.13
- MACD
- AS -0.17
- PODD -0.61
- Stochastic Oscillator
- AS 23.67
- PODD 34.84
About AS AMER SPORTS INC
Amer Sports manages a diverse portfolio of 10 outdoor and action sports brands that collectively generated revenue of $4.4 billion in 2023. Although primarily owned by the Chinese conglomerate Anta Sports, Amer operates with a degree of autonomy. In its rapidly expanding China business, the company is subject to closer oversight, but it manages its operations outside of China with relative independence. In 2023, the firm generates 40% of its revenue from the Americas, 33% from Europe, the Middle East, and Africa, 19% from China, and 7% from Asia-Pacific, excluding China.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.